comparemela.com

Latest Breaking News On - Kapodistrian university of athens school medicine - Page 1 : comparemela.com

Climate change, aging among topics to be highlighted at ENDO 2023

Experts from across the field of endocrinology will converge on Chicago beginning Thursday for the 2023 Endocrine Society annual meeting. ENDO 2023 will take place Thursday through Sunday at the McCormick Place Convention Center in Chicago. After hosting a virtual meeting in 2021 and then a hybrid meeting with in-person and virtual elements in 2022, this year’s conference will take place

PK Modulator Shows Promise in Thalassemia

Dr Magiorkinis: Omicron will probably peak very quickly | ENGLISH

The transmission of the Omicron variant is expected to peak quickly and start to level off within January, based on how it behaved in South Africa, expert epidemiologist and member of the pandemic experts' committee Dr. Gkikas Magiorkinis said in an interview with the Athens-Macedonian News Agency (ANA) radio station 'Praktoreio 104.9 FM' on Monday.

Janssen Announces U S FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse | Antibodies

Hits: 233 DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, PA, USA I July 12, 2021 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The approval follows the regulatory submission to the FDA in November 2020 and marks the sixth indication for DARZALEX

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.